Covalon Technologies Ltd. Highlights VALGuard's Impact on Infection Control at Major Conferences
- Covalon Technologies Ltd. is advancing infection control with its VALGuard device, reducing Central Line-Associated Blood Stream Infections.
- The effectiveness of VALGuard will be presented at major scientific meetings this fall, showcasing Covalon's commitment to healthcare innovation.
- Covalon is dedicated to enhancing patient safety by exploring innovative medical technologies beyond VALGuard.
Covalon Technologies Showcases VALGuard's Potential in Infection Control
Covalon Technologies Ltd. is making significant strides in the healthcare industry with the promising results of its VALGuard Vascular Access Line Guard, which aims to reduce Central Line-Associated Blood Stream Infections (CLABSIs) in critical and acute care units. The findings from a prospective pre- and post-intervention study reveal the device's effectiveness, and the company is set to present these results at two major scientific meetings this fall. The research, which is currently undergoing the publication process in a reputable academic journal, reflects Covalon's dedication to enhancing patient safety through innovative medical technology.
The independent study focuses on the impact of VALGuard in healthcare settings where the risk of infections is heightened, particularly among vulnerable patient populations. By effectively addressing CLABSIs, which can lead to severe complications and extended hospital stays, VALGuard represents a potential breakthrough in infection control. The upcoming presentations at the Association for Vascular Access Annual Scientific Meeting in September and the American Nurses Credentialing Center (ANCC) Magnet Pathway Conference in October offer Covalon an invaluable platform to highlight its findings to an audience of healthcare professionals dedicated to improving clinical outcomes.
Covalon's participation in these conferences is not only a chance to share research findings but also an opportunity to engage with nursing leaders and healthcare innovators from around the world. The ANCC conference, in particular, is expected to draw over 11,000 attendees, providing significant visibility for Covalon's commitment to advancing healthcare practices. By showcasing VALGuard's capabilities, Covalon aims to reinforce its position as a leader in medical technology and contribute positively to the ongoing discourse on patient safety and infection prevention.
In addition to its focus on VALGuard, Covalon continues to explore other innovative solutions in medical technology that can enhance patient care. The company's ongoing research initiatives underscore its strategic commitment to improving clinical outcomes through effective and safe healthcare practices. As the industry evolves, Covalon's expertise in developing advanced medical devices positions it favorably to meet the growing demand for solutions that prioritize patient safety and infection control.